Interpublic Group of Cos.' Lowe, Lintas & Partners Worldwide, New York, was the incumbent. One executive close to the situation said the client and agency had not had "the most rosy relationship."
Lowe held onto the account in a review last year that Zenith participated in. Zenith eventually is expected to add duties for Clarinex, the successor drug to Claritin that the U.S. Food and Drug Administration has said it will not approve for marketing until Schering fixes manufacturing problems. -- Richard Linnett
Copyright March 2001, Crain Communications Inc.